Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
deals
24
×
life sciences
national blog main
san diego blog main
san diego top stories
24
×
startups
24
×
national top stories
biotech
san francisco blog main
boston blog main
new york blog main
boston top stories
new york top stories
san francisco top stories
seattle blog main
wisconsin blog main
wisconsin top stories
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
seattle top stories
texas blog main
texas top stories
boulder/denver blog main
boulder/denver top stories
indiana blog main
indiana top stories
national
cancer
fda
cancer immunotherapy
investing
clinical trials
eli lilly
gene therapy
pfizer
alzheimer's disease
merck
novartis
What
roundup
bio
drug
companies
drugs
cancer
company
deal
new
san
sciences
startup
today
acquisitions
ceo
develop
life
medicines
pfizer’s
pharmaceutical
acquire
advance
ahead
alzheimer’s
amid
asco
big
biggest
biology
biotech
bombast
business
buy
cash
caught
coronavirus
crispr
cytokine
daniel
days
Language
unset
unknown
Current search:
deals
×
startups
×
" san diego top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Spine-Surgery Medtech Startup Carlsmed Merges With Imaging Company
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Meet the Xconomy Awards San Diego Digital Trailblazer Finalists
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
ResMed Boosts Connected Health Play With $225M Propeller Health Deal
@xconomy.com
5 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
Boston Scientific Continues M&A Streak with $202M Deal for Cryterion
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs